Cancer Treatment: Series‑A for NVision Imaging Technologies for USD 30 million.

Ulm, Germany — NVision Imaging Tech­no­lo­gies GmbH has successfully closed a Series A finan­cing round with a volume of more than USD 30 million. Both exis­ting and new inves­tors, inclu­ding promi­nent venture capi­tal inves­tors from the U.S., Israel, Luxem­bourg, Portu­gal and invest­ment compa­nies from German Landes­ban­ken, parti­ci­pa­ted in the finan­cing round to support NVision Imaging Tech­no­lo­gies in the deve­lo­p­ment of meta­bo­lic imaging systems for adap­tive cancer treatment.

NVision Imaging Tech­no­lo­gies GmbH is an award-winning deep-tech startup based in Ulm, Germany, with more than 50 employees from more than 10 count­ries. Foun­ded in 2015, the company lever­a­ges advan­ces in quan­tum physics to enable the first routine, conve­ni­ent, and afforda­ble use of magne­tic reso­nance imaging (MRI) to assess pati­ents’ early response to cancer therapy at the meta­bo­lic level. NVision plans to deploy its pola­ri­zer systems in more than 50 cancer centers world­wide by 2025.

POELLATH has been NVision’s perma­nent legal advi­sor since the begin­ning. In this Series A finan­cing round, POELLATH advi­sed NVision with the follo­wing Munich team:

Dr. Michael Inhes­ter (Part­ner, Lead Part­ner, M&A/ Venture Capital)
Andreas Kühnert, LL.M. (Coun­sel, Co-Lead, M&A/ Venture Capital)
Dr. Nico Fischer (Part­ner, Taxes)
Andreas Gesell (Asso­ciate, Tax)
Leonid Guggen­ber­ger (Asso­ciate, M&A/ Venture Capital)